Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia
Abroad (travel likely)RecruitingPHASE1
Conditions
Recurrent B Acute Lymphoblastic Leukemia · Refractory B Acute Lymphoblastic Leukemia
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
City of Hope Medical Center, Duarte, California, United States
Contact: Principal Investigator (Amandeep Salhotra)
Study leads
Amandeep Salhotra
Principal Investigator
City of Hope Medical Center